Functional p53 determines docetaxel sensitivity in prostate cancer cells

Lycopene Enhances Docetaxel's Effect in Castration-Resistant Prostate Cancer Associated with Insulin-like Growth Factor I Receptor Levels

(2015) Yaxiong Tang et al.   NEOPLASIA

Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer

(2011) M. S. Darshan et al.   CANCER RESEARCH

Camptothecin-induced downregulation of MLL5 contributes to the activation of tumor suppressor p53

(2011) F Cheng et al.   ONCOGENE

Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo

(2011) J.Y. Henry et al.   PROSTATE

Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling

(2011) Lu Gan et al.   PROSTATE

Protein-Protein Interactions Occur Between p53 Phosphoforms and ATM and 53BP1 at Sites of Exogenous DNA Damage

(2011) Shahnaz T. Al Rashid et al.   RADIATION RESEARCH

Docetaxel-based combination therapy for castration-resistant prostate cancer

(2010) M. D. Galsky et al.   ANNALS OF ONCOLOGY

Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer

(2010) M.-L. Zhu et al.   CANCER RESEARCH

p53 binding to the p21 promoter is dependent on the nature of DNA damage

(2010) Ewelina Bodzak et al.   CELL CYCLE

Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer

(2010) Alain G. Musende et al.   PROSTATE

Mathematical model of a network of interaction between p53 and Bcl-2 during genotoxic-induced apoptosis

(2009) Yasam Dogu et al.   BIOPHYSICAL CHEMISTRY

Pharmaceutical Management of Ovarian Cancer

(2008) Maurie Markman   DRUGS

Docosahexaenoic acid enhances the efficacy of docetaxel in prostate cancer cells by modulation of apoptosis: The role of genes associated with the NF-κB pathway

(2008) Irshad A.A. Shaikh et al.   PROSTATE